Markets will remain closed on May 01, 2024 on account of Maharashtra Day.

Sensex Opens Strong; Cadila Healthcare Jumps 3.6%

Fri, 17 Feb 09:30 am

   Previous Close   

   Pre-Open   

   11:30 am   

   01:30 pm   

   Closing   

Asian equity markets are under pressure today as Chinese and Hong Kong indices opened lower. The Shanghai Composite is off 0.30% while the Hang Seng is down 0.44%. The Nikkei 225 is trading down by 0.57%. Share markets in the US & Europe ended their previous session on a weak note.

Meanwhile, share markets in India have opened the trading day firm. The BSE Sensex is trading higher by 262 points while the NSE Nifty is trading higher by 67 points. The BSE Mid Cap index and BSE Small Cap index both have opened the day up by 0.3% & 0.4% respectively.

Sectoral indices have opened the day on a mixed note with information technology stocks and capital goods stocks witnessing selling pressure. While, banking stocks and healthcare stocks are among the top gainers on the BSE. The rupee is trading at 66.95 to the US$.

Pharma stocks have opened the day on a positive note with Elder Pharma and Cadila Healthcare being the most active stocks in this space. Cadila Healthcare share price staged a swift rally (surging 3.6%) after it was reported that its manufacturing facility in Moraiya, Gujarat was inspected by the US Food & Drug Administration (USFDA).

Reportedly, USFDA inspected company's Moraiya facility from 6 February 2017 to 15 February 2017. At the end of the inspection no observation (483) was issued. An FDA Form 483 is issued to firm management after an inspection when an investigator(s) has observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

In the meanwhile, Dr Reddy's Laboratories has received an unfavourable ruling in the US court regarding a patent infringement case over anti-nausea injection Aloxi.

According to reports, New Jersey-based Medicines Co. has filed a suit in a US court alleging Dr. Reddy's is infringing upon its patent to make the generic version of bivalirudin. The drug used as an anticoagulant in angioplasty procedures.

Notably, Aloxi accounts for sales of around US$ 600-650 million in the US. To be sure Dr Reddy's received an approval for generic Aloxi from the USFDA in March 2016, after it settled patent litigations relating to its anti-nausea injection Aloxi.

Innovators in the pharmaceutical industry make use of patents largely. They make heavy use of patents whenever they create a new drug. In one of our recent editions of The Equitymaster Digest, we have spoken everything that you need to know about patented drugs, its advantages and its implications. Here's a snippet:

• "That's how the innovators in the pharmaceutical industry work. They make heavy use of patents whenever they create a new drug. The patent allows them to recoup the high capital expenditure that goes into the research and development (R&D) of new drugs. Companies that have a patent on a particular product are immune from competition for the duration of the patent."

However, the settlement will allow Dr Reddy's to market the generic version of Aloxi in the US, the reports noted. In one of our editions of The 5 Minute WrapUp, we wrote about the USFDA crackdowns faced by the Indian Pharma in the recent times and how they have been constantly investing towards R&D. We believe pharma companies that are upgrading and keeping facilities compliant, and have niche product pipelines in place will see sustained revenue growth going forward.

Dr Reddy's Outperforms BSE-Healthcare Index

Dr Reddy's Lab share price opened the day down by 0.4%.

Moving on to the news from automobile stocks. As per an article in a leading financial daily, Tata Motors and Microsoft India have entered into a partnership for the latter's Connected Vehicle Platform. The partnership will work on solutions for inter-connectivity in cars, autonomous vehicle technology and other services.

Under the partnership, Tata Motors will offer a digital driving experience which will allow drivers and travellers advanced navigation, predictive maintenance and vehicle-centric services, remote monitoring of car features, external mobile experiences and over the air updates.

These offerings will be powered by Microsoft Azure cloud and services such as advanced analytics, machine learning, internet of things and artificial intelligence. The two companies began working with each other last year.

This move will help it make future proof cars in India which in some ways promote the Make in India campaign as well. In a bid to make cars for the future, the company is poised to get into a tie-up with global technology major Microsoft.

With large auto makers already investing in these emerging technologies, it is clear that Tata Motors needs to make the move quickly to avoid losing out the race particularly when also technologically assisted driving can soon become a reality.

To know more about the company's financial performance, subscribers can access to Tata Motors' latest result analysis and Tata Motors stock analysis on our website (subscription required).

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Top Gainers TodayTop Gainers over 1-WeekTop Gainers over 1-MonthTop Gainers over 1-YearTop Gainers over 3-YrsTop Gainers over 5-YrsTop Losers TodayTop Losers over 1-WeekTop Losers over 1-MonthTop Losers over 1-YearTop Losers over 3-YrsTop Losers over 5-YrsOnly BuyersOnly SellersMost Active StocksMost Popular Stocks52 Week High Stocks52 Week Low Stocks

INDICESBSE (Rs 0 to 1)BSE (Rs 1 to 2)BSE (Rs 2 to 4)BSE (Rs 4 to 10)BSE (Rs 10 to 20)BSE (Above Rs 20)BSE - AllBSE-30BSE-100BSE-200BSE-500BSE AutoBSE BankexBSE Capital GoodsBSE Consumer DurablesBSE FMCGBSE HealthcareBSE ITBSE MetalBSE Oil & GasBSE PSUBSE TeckBSE RealtyBSE PowerBSE A GroupBSE B GroupBSE Mid-CapBSE Small-CapBSE Basic MaterialsBSE Consumer DiscretionaryBSE IndustrialsBSE UtilitiesBSE Sensex 50BSE Sensex Next 50BSE Bharat 22BSE 150 MidCapBSE 250 SmallCapBSE 250 LargeMidCapBSE 400 MidSmallCapBSE AllCapBSE LargeCapBSE SmallCap SelectBSE 100 LargeCap TMCBSE InfraBSE ManufacturingBSE CPSEBSE Private BankBSE Diversified FinancialsBSE MomentumBSE Low VolatilityBSE QualityBSE Enhanced ValueBSE Divident StabilityS&P BSE IPOBSE SMEIPOBSE 100 ESGBSE CarbonexBSE GreenexNSE (Rs 0 to 10)NSE (Rs 10 to 20)NSE (Above Rs 20)NSE - AllNSE-50NSE ITNSE Nifty Midcap 50NSE JR. NiftyNSE Bank NiftyNIFTY Next 50NIFTY 100NIFTY 200NIFTY 500NIFTY MidCap 100NIFTY SmallCap 250NIFTY SmallCap 50NIFTY SmallCap 100NIFTY LargeMidCap 250NIFTY MidSmallCap 400NIFTY AutoNIFTY Consumer DurablesNIFTY FinanceNIFTY FMCGNIFTY MediaNIFTY MetalNIFTY PharmaNIFTY Private BankNIFTY PSU BankNIFTY RealtyNIFTY Oil & GasNIFTY SME EmergeNIFTY CommoditiesNIFTY CPSENIFTY EnergyNIFTY India ConsumptionNIFTY InfraNIFTY MNCNIFTY PSENIFTY Serv SectorNIFTY100 Liquid 15NIFTY Midcap Liquid 15NIFTY Midcap 150 Quality 50NIFTY50 Equal WeightNIFTY100 Equal WeightNIFTY100 Low Volatility 30NIFTY100 Alpha 30NIFTY Alpha 50NIFTY Dividend Opportunities 50NIFTY High Beta 50NIFTY Low Volatility 50NIFTY200 Quality 30NIFTY 500 Value 50NIFTY 100 Quality 30SECTORSAgricultureAirlinesAluminiumAsset Management CompaniesAutomobilesAuto AncillariesBanks (Private)Banks (PSU)BankingCementChemicalsDefenceDiagnosticsDronesEngineeringElectric VehicleElectric Vehicle BatteryEnergy SourcesESGEthanolFertilizersFintechFMCGFoodGreen HydrogenHotelsInfrastructureInsuranceInvestment and FinanceInvITIT (Large)IT (Others)LogisticsMediaMetalMiningIndia's Big Tech StocksIndian PharmaMNC PharmaPSUPaintPaperPlasticPowerRating AgenciesReal EstateREITsRenewable EnergyRetailingSemiconductorShippingSteelSugarSupply ChainTelecomTextilesTravel Support Services

10 results 25 results 50 results 100 results All results

Indian Share Market Update: Top Gainers and Losers